(Sharecast News) - Drugmaker AstraZeneca said on Tuesday that its Koselugo asset has been approved for usage in the European Union for the rare, progressive, genetic condition, plexiform neurofibromas, in adults with neurofibromatosis type 1.
AstraZeneca stated the European Commission's approval follows the positive opinion of the Committee for Medicinal Products...

Email this article to a friend

or share it with one of these popular networks:

• DIGG
• FACEBOOK
• STUMBLEUPON
• MIXX
• YAHOO BUZZ
• DELICIOUS
• REDDIT
• NEWSVINE